<DOC>
	<DOCNO>NCT00158548</DOCNO>
	<brief_summary>Chloroquine resistant falciparum malaria Pakistan prevalent every malarious area examine . Resistance favour second-line treatment , sulphadoxine-pyrimethamine S/P rise fast . To avert repetition resistance catastrophe occur SE Asia critical preserve effective life SP use combination artesunate . Efficacy ACT artesunate combination chloroquine , SP amodiaquine treatment malaria ( falciparum vivax ) examine malaria patient Pakistan .</brief_summary>
	<brief_title>ACT With Chloroquine , Amodiaquine &amp; Sulphadoxine-pyrimethamine Pakistan</brief_title>
	<detailed_description>The incidence falciparum malaria Pakistan rise 6-fold last 15 year chloroquine resistance prevalent every malarious area examine . Chloroquine 's position first line treatment must reconsider . Resistance favour second-line treatment , sulphadoxine-pyrimethamine SP , 10 % rise fast . It critical preserve effective life SP use combination non-related fast-acting antimalarial artesunate ( AS ) . It conceivable use AS combination chloroquine might even recover latter 's effectiveness restrain selection strong level chloroquine resistance . To determine tolerability efficacy AS combination therapy subcontinent , randomize control trial conduct HealthNet International government staff , technical support LSHTM , Afghan refugee camp Pakistan current therapy chloroquine , amodiaquine SP . Current policy use primaquine ( PQ ) gametocytocidal drug CQ SP . It clear whether value face high level CQ resistance . The efficacy PQ combination CQ SP examine individual randomise trial comparison CQ SP alone . In past , treatment falciparum vivax malaria chloroquine . With development drug resistance treatment two specie diverge place high priority accurate differential diagnosis always meet peripheral health post . There may advantage harmonise treatment two specie ACT . Thus current treatment vivax , chloroquine , shall compare ACT artesunate SP , likely ACT adopt falciparum malaria . Protocol design : Randomised , single-blind , controlled trial compare falciparum malaria ( 1 ) artesunate ( AS ) chloroquine ( CQ ) , vs CQ alone , vs CQ primaquine ( PQ ) ; ( 2 ) AS sulphadoxine-pyrimethamine ( SP ) , vs SP alone , vs SP PQ ; ( 3 ) AS amodiaquine ( AQ ) , vs AQ alone . Randomised , single-blind , controlled trial compare vivax malaria : AS sulphadoxine-pyrimethamine ( SP ) , vs CQ alone . Patients randomly assign one follow treatment group : - CQ ( day1,2,3 ) + placebo ( day 1 , 3 ) v - CQ ( day 1,2,3 ) + PQ ( day 1 ) + placebo ( day 3 ) v - CQ ( day 1,2,3 ) + PQ ( day 3 ) + placebo ( day 1 ) v - CQ ( day 1,2,3 ) + AS ( day 1 ) + placebo ( day 3 ) - S/P ( day 1 ) + placebo ( day 1 ) v - S/P ( day 1 ) + AS ( day 1 ) v - S/P ( day 1 ) + PQ ( day 1 ) - AQ ( day 1,2,3 ) + placebo ( day 1,2,3 ) v - AQ ( day 1,2,3 ) + AS ( day 1,2,3 ) To determine viability transmissibility gametocyte ( also detect sub-patent gametocytaemias ) still present treatment also propose carry mosquito feed study directly patient 7th day start combination therapy either CQ , CQ+AS , CQ+PQ. , SP , SP+AS , SP+PQ incubate midgut infection oocyst stage . To determine genetic consequence selection different drug ( i.e . CQ , AS , PQ ) , mosquito midgut infection would preserve genetic study UK , would blood sample take initial recrudescent infection . To improve understanding genetic basis drug resistance genotype parasites blood sample patient treatment failure study . Blood sample 20 patient arm study parasitological treatment failure select randomly , together midgut infection , analyse genetic marker resistance chloroquine sulphadoxine/pyrimethamine . These compare genotype pre-treatment infection .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Malaria , Vivax</mesh_term>
	<mesh_term>Fanasil , pyrimethamine drug combination</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<mesh_term>Sulfadoxine</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Pyrimethamine</mesh_term>
	<mesh_term>Primaquine</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<criteria>adult child &gt; 5 yr weight &gt; 5 kg monoinfection P. falciparum P. vivax history recent fever consent patient parent . patient sign severe malaria .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Falciparum</keyword>
	<keyword>Vivax</keyword>
	<keyword>Treatment</keyword>
	<keyword>Asia</keyword>
</DOC>